Thymosin β4 and the TB-500 Fragment

Thymosin β4 (Tβ4) is a 43-amino acid peptide ubiquitous in mammalian cells — with intracellular concentrations of 0.5–1 mM in platelets and leukocytes — whose primary documented function is sequestration of G-actin (globular monomeric actin) to regulate the pool available for polymerization. TB-500 in the research context typically denotes a complete synthetic Tβ4 preparation (43 residues) or, in specific formulations, the Ac-SDKP fragment (Acetyl-Ser-Asp-Lys-Pro, also termed the N-terminal tetrapeptide) from the N-terminal region of Tβ4. The distinction is pharmacologically relevant: the full Tβ4 molecule (molecular weight ~4964 Da) contains both the LKKTET actin-binding domain and the N-terminal angiogenic domain, while the Ac-SDKP fragment (~430 Da) retains angiogenic and immunomodulatory activity but lacks the LKKTET actin-binding domain. Research studies on TB-500 generally use the full Tβ4 molecule.

G-Actin Sequestration Mechanism: The LKKTET Domain

The actin cytoskeleton exists in dynamic equilibrium between G-actin (monomer) and F-actin (filament). Tβ4 binds G-actin with a KD of approximately 0.7 μM through its central LKKTET domain (residues 17–22), forming a 1:1 complex that caps the monomer's (+) end and prevents incorporation into filaments. Tβ4 functions as a G-actin buffer: when the cell requires actin polymerization (during migration, division, or contraction), demand for G-actin dissociates the Tβ4:actin complex. In direct binding studies with purified muscle actin, the KD of Tβ4 for G-actin is 0.5–0.9 μM depending on ionic conditions; selectivity for G-actin over F-actin exceeds 1000-fold. Tβ4 expression is upregulated during the migratory phase of wound healing in multiple cell types including keratinocytes, fibroblasts, and endothelial cells.

ILK/PINCH/Parvin Signaling and Integrin Activation

Beyond G-actin sequestration, Tβ4 promotes signaling through the ILK (integrin-linked kinase)/PINCH/parvin ternary complex, a central regulator of integrin-mediated cell adhesion. ILK, a structurally active serine/threonine kinase, binds the cytoplasmic tail of integrin β1 and integrin β3, recruiting parvin (α-parvin or β-parvin) through the PINCH adaptor. ILK/PINCH/parvin complex activation regulates Akt phosphorylation at Ser473 and GSK-3β at Ser9, connecting extracellular adhesion to survival pathways (PI3K/Akt/mTOR) and cytoskeletal stabilization. Tβ4 upregulates integrin β1 expression in human keratinocytes by 35–50% (flow cytometry) at concentrations of 100–300 ng/mL, promoting adhesion to fibronectin — the primary ligand for integrins α5β1 and αVβ3 — and facilitating directed migration in the wound repair context.

VEGF Signaling and Angiogenesis

Tβ4 upregulates VEGF expression in cardiac fibroblasts and endothelial cells through a HIF-1α-dependent mechanism: Tβ4 stabilizes HIF-1α by interfering with the prolyl-4-hydroxylase-dependent hydroxylation pathway that directs HIF-1α toward proteasomal degradation under normoxia. In HUVEC cultures, Tβ4 at 100–500 ng/mL increases VEGF-A expression by 40–60% (RT-PCR), scratch assay migration by 45–65% over control at 16–24h, and Matrigel tube formation (total tube length) by 35–55% (p<0.01). In the chicken chorioallantoic membrane (CAM) model, Tβ4 at 1–10 μg per implant increases vascular density by 30–45% over control (p<0.05).

Preclinical Data and Quality Specifications

In full-thickness cutaneous wound healing models in C57BL/6J mice (6mm punch biopsy), topical or systemic Tβ4 (1–100 μg/day) accelerates wound closure by 20–35% versus controls at day 7 (p<0.05), with greater neovascularization density (CD31+) and higher α-SMA+ cell count (myofibroblasts) at the healing front. In left coronary artery ligation myocardial infarction models in mice, systemic Tβ4 (300 μg/mouse IP post-infarct) reduces fibrosis zone (Masson trichrome, percentage area) by 25–35% at 4 weeks. For reproducible research, TB-500 (full Tβ4) must meet: ≥98% purity by HPLC-UV at 214 nm; identity confirmed by ESI-MS or MALDI-TOF with mass of 4964.2 ± 0.5 Da; endotoxins <1 EU/mg; counterion form specified. Alpha Nordisk supplies TB-500 under lot A26Q2TBF0488 with CoA verifiable at alphanordisk.com/verify. For research and laboratory use. Not for unsupervised human consumption.